U.S. FDA Approves INVOKANA® (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease

Press/Media: Press / Media

PeriodOct 30 2018 → Oct 31 2018

Media coverage

9

Media coverage

  • TitleU.S. FDA Approves INVOKANA® (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
    Media name/outletPipelineReview
    CountrySpain
    Date10/31/18
    PersonsRalph A Defronzo
  • TitleU.S. FDA Approves INVOKANA® (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
    Media name/outletJanssen
    CountryUnited States
    Date10/31/18
    PersonsRalph A Defronzo
  • TitleU.S. FDA Approves INVOKANA® (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
    Media name/outletPR Newswire
    CountryUnited States
    Date10/30/18
    PersonsRalph A Defronzo
  • TitleU.S. FDA Approves INVOKANA® (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
    Media name/outletTickerTech.com
    CountryUnited States
    Date10/30/18
    PersonsRalph A Defronzo
  • TitleU.S. FDA Approves INVOKANA® (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
    Media name/outletBioSpace
    CountryUnited States
    Date10/30/18
    PersonsRalph A Defronzo
  • TitleU.S. FDA Approves INVOKANA® (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
    Media name/outletWFMJ 21 - TV
    CountryUnited States
    Date10/30/18
    PersonsRalph A Defronzo
  • TitleU.S. FDA Approves INVOKANA® (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
    Media name/outletFOX 14 TV
    CountryUnited States
    Date10/30/18
    PersonsRalph A Defronzo
  • TitleU.S. FDA Approves INVOKANA® (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
    Media name/outletThe Business Journals
    CountryUnited States
    Date10/30/18
    PersonsRalph A Defronzo
  • TitleU.S. FDA Approves INVOKANA® (canagliflozin) to Reduce the Risk of Heart Attack, Stroke or Cardiovascular Death in Adults with Type 2 Diabetes and Established Cardiovascular Disease
    Media name/outletKOAM TV
    CountryUnited States
    Date10/30/18
    PersonsRalph A Defronzo